Tatva Chintan Pharma Chem Ltd. reported robust Q1 financial results. Revenue from operations increased by 10.8% to ₹1,168.64 crore, while profit after tax surged by 27.7% to ₹66.51 crore. EBITDA expanded by 37.4% to ₹173.30 crore, with operating margins improving to 14.8%. The company saw growth across product categories, particularly in Structure Directing Agents and Pharma & Agrochemical Intermediates segments. The strong performance is attributed to an improved product mix, operational efficiency, and market expansion. With a strong order book and ongoing capacity expansion, Tatva Chintan is positioned for continued growth.
24Jul 25
Tatva Chintan Reports Strong Q1 Performance with 11% Revenue Growth
Tatva Chintan Pharma announced robust Q1 financial results, with consolidated revenue increasing 11% to ₹1,168.64 crore. EBITDA rose 37% year-on-year to ₹173.30 crore, with the margin expanding to 14.8%. Net profit grew 28% to ₹66.50 crore, and EPS increased to ₹2.84. The company's diverse product portfolio contributed to growth, with Pharma & Agrochemical Intermediates (PASC) being the largest segment at 37% revenue contribution. Management changes were announced, including re-appointments of key directors and the resignation of the CFO.
24Jul 25
Tatva Chintan Reports Q1 Results, Approves Director Reappointments and CFO Resignation
Tatva Chintan Pharma Chem Limited reported strong Q1 results with a 10.8% increase in revenue to Rs 1,168.64 million and a 27.7% rise in net profit to Rs 66.51 million. EBITDA grew by 37.4% to Rs 173.30 million, with margin improvement to 14.8%. The Board approved reappointments of key executives and independent directors. CFO Ashok Bothra resigned effective August 30, 2025. The company's product segments showed diverse revenue contributions, with Pharma & Agrochemical Intermediates leading at 37%.
Shares of Tatva Chintan Pharma Chem Limited rose 13.6% to Rs 1,062.70 after prominent investor Mukul Agrawal acquired a 1.28% stake (3 lakh shares) in the company. The stock has rallied 21.4% year-to-date, recovering from a previous 65% decline from its peak. Domestic mutual funds slightly reduced their stake to 5.07%, while Goldman Sachs maintained a 2.59% stake. The company has scheduled a Board meeting and earnings call for July 24 to discuss Q1 FY24 financial results.
18Jul 25
Mukul Mahavir Agrawal Acquires 1.28% Stake in Tatva Chintan Pharma Chem; Company Announces Q1 FY26 Board Meeting
Tatva Chintan Pharma Chem Limited reports a 1.28% stake acquisition by investor Mukul Mahavir Agrawal. The company has scheduled a board meeting on July 24, 2025, to approve Q1 FY26 financial results. An earnings call will follow, featuring key company executives. The trading window for designated persons will be closed from July 1, 2025, until 48 hours after the results announcement.
17Jul 25
Mukul Mahavir Agrawal Acquires 1.28% Stake in Tatva Chintan Pharma Chem; Company Schedules Q1 FY26 Results
Investor Mukul Mahavir Agrawal has acquired a 1.28% stake in Tatva Chintan Pharma Chem Limited during the first quarter. The company's Board of Directors will meet on July 24, 2025, to approve Q1 FY26 financial results, followed by an earnings call featuring key company representatives. The trading window for the company's equity shares will be closed from July 1, 2025, until 48 hours after the Q1 FY26 results are made public.
18Jun 25
CRISIL Downgrades Tatva Chintan Pharma Chem's Ratings Amid Business Challenges
CRISIL has downgraded Tatva Chintan Pharma Chem Ltd's ratings on bank facilities worth ₹245.00 crore. Long-term rating revised from A- (negative) to BBB+ (stable), and short-term rating from A2+ to A2. The downgrade is due to expected revenue decline to ₹385.00 crore and operating profit margin compression to 9.49% from 18.43%.
05May 25
Tatva Chintan Pharma Chem Secures ₹29.95 Crore Export Order for Specialty Chemicals
Tatva Chintan Pharma Chem Limited has received a significant export order worth ₹29.95 crore (USD 3.56 million) for supplying specialty chemicals in the Pharma & Agro Intermediates & Specialty Chemicals (PASC) category. The order, placed by an international client, is set for delivery in November/December 2025. This development is expected to boost the company's revenue for Q3 FY26 and strengthen its position in the global specialty chemicals market.
Tatva Chintan Pharma Chem Ltd. (TCPCL) reported a significant improvement in Q4 FY2024-25 financials. Net profit rose to ₹10.30 crore from ₹1.38 crore in Q3, though down from ₹96.00 crore year-over-year. Revenue increased by 5.64% YoY to ₹108.60 crore. The company showed substantial QoQ improvements in revenue (26.43% increase) and EBITDA (36.62% increase). Despite YoY challenges, TCPCL demonstrated resilience with improved quarterly performance. A final dividend of ₹1.00 per equity share was recommended.
Tatva Chintan Pharma Chem Limited reported mixed financial results for Q4 and FY 2024-25. Q4 revenue increased 9.80% YoY to ₹1,078.64 crore, but net profit fell to ₹10.30 crore from ₹96.14 crore. FY25 saw a marginal decrease in annual revenue to ₹3,827.14 crore, with net profit declining 68.30% to ₹96.14 crore. Despite challenges, a final dividend of ₹1 per share was recommended. The company faces profitability pressures but shows resilience in revenue growth amid sector headwinds.